Author:
Calvo-Schimmel Alejandra,Hammer Marilyn J.,Wright Alexi A.,Blank Stephanie V.,Cohen Bevin,Harris Carolyn,Shin Joosun,Conley Yvette,Paul Steven,Cooper Bruce,Levine Jon D.,Miaskowski Christine
Abstract
Background
Depression is a pervasive symptom in patients with gynecological cancer undergoing chemotherapy.
Objectives
Purposes were to identify subgroups of patients with distinct depression profiles and evaluate for differences in demographic and clinical characteristics, severity of common symptoms, and quality of life (QOL) outcomes among these subgroups.
Methods
Patients with gynecological cancer (n = 231) completed the Center for Epidemiologic Studies–Depression Scale 6 times over 2 cycles of chemotherapy. All of the other measures were completed prior to the second or third cycle of chemotherapy. Latent profile analysis was done to identify the distinct depression profiles. Differences were evaluated using parametric and nonparametric tests.
Results
Three distinct profiles were identified: low (60.1%), high (35.1%), and very high (4.8%). Compared with low class, the other 2 classes had lower functional status and were more likely to self-report a diagnosis of depression. Patients in the 2 worse profiles reported a higher comorbidity burden, higher levels of trait and state anxiety, sleep disturbance, and fatigue, as well as lower levels of cognitive function and poorer QOL. State and trait anxiety, evening fatigue, and sleep disturbance scores exhibit a “dose-response effect” (ie, as the depression profile worsened, the severity of these symptoms increased).
Conclusions
Almost 40% of our sample experienced high or very high levels of depression across 2 cycles of chemotherapy.
Implications for Practice
Clinicians can use the identified risk factors to identify high patients risk and provide tailored psychological interventions aimed to decrease symptom burden and prevent decrements in QOL.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Oncology (nursing),Oncology
Reference61 articles.
1. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates;BMJ Open,2015
2. The prevalence of depression and anxiety in women with ovarian cancer: an updated systematic review and meta-analysis of cross-sectional studies;Res Square,2022
3. Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review;Int J Womens Health,2017
4. Prevalence of depression among adults aged 20 and over: United States, 2013-2016;NCHS Data Brief,2018
5. Depression in cancer patients undergoing chemotherapy in a tertiary care hospital of North Bengal, India;Indian J Public Health,2017